Article
Oncology
Guanghao Wu, Biying Chen, Junjie Jiang, Yiran Chen, Yanyan Chen, Haiyong Wang
Summary: This study reveals the predictive capability of pyroptosis in immunotherapy for melanoma. By developing a pyroptosis-based model, it is reliable to predict the clinical benefits and survival outcomes of melanoma patients receiving immunotherapy.
Article
Oncology
Arran Hodgkinson, Dumitru Trucu, Matthieu Lacroix, Laurent Le Cam, Ovidiu Radulescu
Summary: This study explores the relationship between melanoma cell heterogeneity and drug resistance by introducing a new mathematical formalism. Using single cell mRNA sequencing data, the researchers propose different therapeutic strategies for melanoma and predict their outcomes.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Joanna Lee, Tasnia Ahmed, Andrea Maurichi, Lorenzo Di Guardo, Anna M. Stagno, Lydia Warburton, Amelia. M. Taylor, Elisabeth Livingstone, Saba Rehman, Adnan Khattak, Katharina C. Kahler, Vito Vanella, Victoria Atkinson, Michael Millward, Dirk Schadendorf, Douglas B. Johnson, Paolo A. Ascierto, Axel Hauschild, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies, Matteo S. Carlino
Summary: For patients with advanced melanoma, there is a risk of recurrence after discontinuation of targeted therapy, but retreatment with targeted therapy shows a high response rate.
EUROPEAN JOURNAL OF CANCER
(2023)
Review
Dermatology
Francesca Aroldi, Mark R. Middleton
Summary: Advances in the understanding of melanoma biology and immunology have led to the development of immune checkpoint inhibitors, which have shown impressive long-lasting responses in the treatment of melanoma. However, the toxicity of these drugs remains a significant concern.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
(2022)
Article
Oncology
Lidia Szatkowska, Jan Sieczek, Katarzyna Tekiela, Marcin Zietek, Paulina Stachyra-Strawa, Pawel Cisek, Rafal Matkowski
Summary: This study evaluated risk factors and treatment outcomes for advanced malignant melanoma with anti-PD-1 antibodies and BRAF/MEK inhibitors, finding that the BRAF mutation significantly affects disease recurrence after surgery and recommending close monitoring and consideration of BRAF/MEK inhibitor treatment for V600 mutation patients.
Article
Immunology
Jingjing Zhao, Dandan Li, Songzuo Xie, Xinpei Deng, Xizhi Wen, Jingjing Li, Zhengrong Wu, Xinyi Yang, Minxing Li, Yan Tang, Xiaoshi Zhang, Ya Ding
Summary: This study found that baseline biomarkers can predict the response to immunotherapy and prognosis in patients with metastatic melanoma. Personalized treatment regimens can be developed based on these biomarkers.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Abhinav Jaiswal, Akanksha Verma, Ruth Dannenfelser, Marit Melssen, Itay Tirosh, Benjamin Izar, Tae-Gyun Kim, Christopher J. Nirschl, K. Sanjana P. Devi, Walter C. Olson, Craig L. Slingluff, Victor H. Engelhard, Levi Garraway, Aviv Regev, Kira Minkis, Charles H. Yoon, Olga Troyanskaya, Olivier Elemento, Mayte Suarez-Farinas, Niroshana Anandasabapathy
Summary: Better classification and understanding of tumor-infiltrating lymphocytes (TILs) is needed. This study found enrichment of T memory/resident memory programs in solid tumors compared to other T cell states. Single-cell analysis of melanoma CD8(+) TILs revealed a high proportion of memory/resident memory-scoring TILs in responders to anti-PD-1 therapy. TILs scoring highly for early T cell activation, but not exhaustion, were associated with non-response. Late/persistent activation signatures were predictive of melanoma survival and co-expressed with dendritic cell and IFN-gamma response programs.
Article
Oncology
Ruth Board, Rebecca Smittenaar, Sarah Lawton, Hanhua Liu, Bukky Juwa, David Chao, Pippa Corrie
Summary: Immune checkpoint inhibitors have demonstrated good survival rates in patients with metastatic melanoma and can achieve predicted outcomes from RCTs in routine care settings in England. Differences in patient age and health status between different CPI treatments may impact treatment outcomes and rates of adverse events.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Article
Oncology
Elizabeth M. Gaughan, Bethany J. Horton
Summary: The study found that receiving chemotherapy after immunotherapy for metastatic melanoma did not significantly improve outcomes, but it may still provide palliative benefits for some patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Medicine, General & Internal
Paul Nathan, Jessica C. Hassel, Piotr Rutkowski, Jean-Francois Baurain, Marcus O. Butler, Max Schlaak, Ryan J. Sullivan, Sebastian Ochsenreither, Reinhard Dummer, John M. Kirkwood, Anthony M. Joshua, Joseph J. Sacco, Alexander N. Shoushtari, Marlana Orloff, Josep M. Piulats, Mohammed Milhem, April K. S. Salama, Brendan Curti, Lev Demidov, Lauris Gastaud, Cornelia Mauch, Melinda Yushak, Richard D. Carvajal, Omid Hamid, Shaad E. Abdullah, Chris Holland, Howard Goodall, Sophie Piperno-Neumann
Summary: The randomized trial of tebentafusp for metastatic uveal melanoma showed a higher 1-year overall survival rate among patients who received tebentafusp compared to those who received the investigator's choice of therapy, indicating superior efficacy.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Oncology
Adi Diab, Scott S. Tykodi, Gregory A. Daniels, Michele Maio, Brendan D. Curti, Karl D. Lewis, Sekwon Jang, Ewa Kalinka, Igor Puzanov, Alexander Spira, Daniel C. Cho, Shanhong Guan, Erika Puente, Tuan Nguyen, Ute Hoch, Sue L. Currie, Wei Lin, Mary A. Tagliaferri, Jonathan Zalevsky, Mario Sznol, Michael E. Hurwitz
Summary: This study found that the combination of BEMPEG and NIVO showed promising antitumor activity in first-line metastatic melanoma, including extended median progression-free survival. Early on-treatment blood biomarkers were associated with treatment response.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Mathematical & Computational Biology
Jiaping Wang
Summary: This study identified hub genes related to the progression of SKCM through comprehensive analysis of RNA sequencing datasets. By constructing predictive and nomogram models, independent clinicopathologic factors were identified, and a predictive model for estimating individual survival probabilities was developed.
MATHEMATICAL BIOSCIENCES AND ENGINEERING
(2021)
Article
Oncology
Cecilia Jiang, Troy J. Kleber, Jeffrey M. Switchenko, Mohammad K. Khan
Summary: This study retrospectively reviewed 63 MBM patients treated with WBRT at a single institution from 2000 to 2018, finding that WBRT remains an effective treatment strategy for controlling intracranial disease with limited treatment-related toxicities. Performance status and the use of BRAF inhibitors were associated with overall survival, highlighting the potential impact of systemic therapy in improving outcomes for MBM patients.
RADIATION ONCOLOGY
(2021)
Article
Oncology
Silke Gillessen, Nicolas Sauve, Laurence Collette, Gedske Daugaard, Ronald de Wit, Costantine Albany, Alexey Tryakin, Karim Fizazi, Olof Stahl, Jourik A. Gietema, Ugo De Giorgi, Fay H. Cafferty, Aaron R. Hansen, Torgrim Tandstad, Robert A. Huddart, Andrea Necchi, Christopher J. Sweeney, Xavier Garcia-Del-Muro, Daniel Y. C. Heng, Anja Lorch, Michal Chovanec, Eric Winquist, Peter Grimison, Darren R. Feldman, Angelika Terbuch, Marcus Hentrich, Carsten Bokemeyer, Helene Negaard, Christian Fankhauser, Jonathan Shamash, David J. Vaughn, Cora N. Sternberg, Axel Heidenreich, Jorg Beyer
Summary: This study updated and adjusted the classification of metastatic nonseminomatous germ cell tumors, providing a more detailed and personalized assessment of patient prognosis. The new prognostic model identified a new cutoff value for lactate dehydrogenase, increasing age, and the presence of lung metastases as additional adverse prognostic factors.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Wei Li, Xuewen Xu, Yange Zhang
Summary: In this study, nomograms based on the number of positive LNs and other clinicopathologic characteristics showed good predictive ability for predicting the survival of CM patients. The two nomograms demonstrated better predictive values compared to the American Joint Committee on Cancer 7th edition staging system, with good coordination and net benefit in both the PLNnone/single and PLNmultiple cohorts.
ANNALS OF SURGICAL ONCOLOGY
(2021)
